CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.
[2]
Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma(中国临床肿瘤学会原发性肝癌诊疗指南)[M]. Beijing: Peaple’s Medical Publishing House, 2018.
[3]
Bureau of Medical Administration, National Health and Family Planning Comission of the PRC. Standardization of diagnosis and treatment for hepatocellular carcinoma (2017 edition) [J]. Chin J Digest Surg(中华消化外科杂志), 2017,16(7): 635-647.
[4]
National Comprehensive Cancer Network. Hepatobiliary Cancer (version 1.2019)[S/OL]. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
[5]
QIN S, BAI Y, LIM H Y, et al. Randomized,multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
[6]
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemensis, Version 3. 2018. https://www. nccn. org/professionals/physician_gls/pdf/antiemesis.pdf.
[7]
LLOVET J M, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
[8]
CHENG A L, KANG Y K, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
[9]
KUDO M, FINN R S, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 noninferioritytrial[J].Lancet, 2018, 391(10126):1163-1173.
[10]
BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66.
[11]
EL-KHOUEIRY A B, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
[12]
ZHU A X, FINN R S, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a nonrandomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7):940-952.
2019, Vol. 54 
